جاري التحميل…
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy
BACKGROUND: The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma in a phase 2, proof-of-concept study. RESULT...
المؤلفون الرئيسيون: | , , , , , |
---|---|
التنسيق: | نص |
اللغة: | English |
منشور في: |
BioMed Central
2010
|
الموضوعات: | |
الوصول للمادة أونلاين: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856553/ https://www.ncbi.nlm.nih.gov/pubmed/20350333 http://dx.doi.org/10.1186/1476-4598-9-69 |